Peter Attia· MD
so we're using the same clinical instruments to measure pain and function we're similar dose levels so we're doing placebo half MIG two MiG's four MiG's okay which was the highest dose that we explored in the phase one study
Loading…
The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
so we're using the same clinical instruments to measure pain and function we're similar dose levels so we're doing placebo half MIG two MiG's four MiG's okay which was the highest dose that we explored in the phase one study
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.
and it's 45 patients per dose level as opposed to six so we should have sufficient statistical power to really see this really clearly
so there's 12 placebos 36 treatments treated patients and those 36 treated patients were about 6 per dose they were 6 per dose yeah so we had 6 dose levels
and in terms of the criteria of the patients that are coming in they have to have painful osteoarthritis of the knee and so there is a score this thing called the NRS which is this numerical rating scale this is this zero to ten so it's an 11-point scale and you have to be between a four and a nine